UK Approves Lilly's Oral Obesity Drug Foundayo; $3.5B U.S. Plant Plan Unveiled
LLY sits 97% above its 52-week low of $623.78.
Summary
The UK MHRA approved Lilly's oral GLP-1 Foundayo for weight management and type 2 diabetes, marking the first major market authorization for the drug. This follows the FDA approval noted in the August 5 10-Q and adds a key international regulatory win. Separately, Lilly announced plans for four new U.S. plants, including a $3.5 billion site in Pennsylvania, to expand domestic production capacity. The manufacturing investment signals confidence in long-term demand for its obesity and diabetes portfolio. Shares rose about 2.1% on the news.
At the time of this announcement, LLY was trading at $1,229.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.